Adult Polyglucosan Body Disease: A Rare Presentation with Chronic Liver Disease and Ground-Glass Hepatocellular Inclusions

ABSTRACT

Liver involvement in genetic and metabolic disorders may result in intrahepatic accumulation of specific precursors or byproducts, which have distinctive features on light microscopy. The “polyglucosan disorders” are diseases in which polyglucosan (abnormal glycogen with decreased branching) is formed and deposited in various tissues because of decreased or absent glycogen branching enzyme activity. These disorders include Lafora disease (myoclonus epilepsy) and type IV glycogen storage disease. Polyglucosan deposits in both conditions result in ground-glass hepatocellular inclusions resembling those seen in chronic hepatitis B virus infection. In the present report, we describe a case of the rare, adulthood form of glycogen branching enzyme deficiency, adult polyglucosan body disease (APBD), in which abnormal serum liver tests prompted a liver biopsy. The pathologic findings of periportal ground-glass hepatocellular inclusions, mild chronic portal inflammation, and periportal fibrosis are not well described in APBD, but resemble the chronic changes that have been reported in Lafora disease. The differential diagnosis of ground-glass hepatocytes and the genetic basis of APBD are discussed.

KEYWORDS

Liver - adult polyglucosan body disease - type IV glycogenosis - ground-glass - hepatitis B - Lafora disease

REFERENCES

• 1 Portmann B C, Thompson R J, Roberts E A, Paterson A C. Genetic and metabolic liver disease. In: Burt A D, Portmann B C, Ferrell L D, eds. MacSween's Pathology of the Liver. 5th ed. Edinburgh: Elsevier; 2007: 199-326
• 2 Nishimura R N, Ishak K G, Reddick R, Porter R, James S, Barranger J A. Lafora disease: diagnosis by liver biopsy.  Ann Neurol. 1980;  8 (4) 409-415
• 3 Suzuki K, David E, Kutschman B. Presenile dementia with “Lafora-like” intraneuronal inclusions.  Arch Neurol. 1971;  25 (1) 69-80
• 4 Klein C J, Boes C J, Chapin J E et al.. Adult polyglucosan body disease: case description of an expanding genetic and clinical syndrome.  Muscle Nerve. 2004;  29 (2) 323-328
• 5 Lossos A, Klein C J, McEvoy K M, Keegan B M. A 63-year-old woman with urinary incontinence and progressive gait disorder.  Neurology. 2009;  72 (18) 1607-1613
• 6 Sindern E, Ziemssen F, Ziemssen T et al.. Adult polyglucosan body disease: a postmortem correlation study.  Neurology. 2003;  61 (2) 263-265
• 7 Roe C R, Bottiglieri T, Wallace M, Arning E, Martin A. Adult polyglucosan body disease (APBD): anaplerotic diet therapy (Triheptanoin) and demonstration of defective methylation pathways.  Mol Genet Metab. 2010;  101 (2-3) 246-252
• 8 Hadziyannis S, Gerber M A, Vissoulis C, Popper H. Cytoplasmic hepatitis B antigen in “ground-glass” hepatocytes of carriers.  Arch Pathol. 1973;  96 (5) 327-330
• 9 Vázquez J J. Ground-glass hepatocytes: light and electron microscopy. Characterization of the different types.  Histol Histopathol. 1990;  5 (3) 379-386
• 10 Wills E J. Ground glasslike hepatocytes produced by glycogen-membrane complexes (“glycogen bodies”).  Ultrastruct Pathol. 1992;  16 (4) 491-503
• 11 Callea F, de Vos R, Togni R, Tardanico R, Vanstapel M J, Desmet V J. Fibrinogen inclusions in liver cells: a new type of ground-glass hepatocyte. Immune light and electron microscopic characterization.  Histopathology. 1986;  10 (1) 65-73
• 12 Bruguera M, Lamar C, Bernet M, Rodés J. Hepatic disease associated with ground-glass inclusions in hepatocytes after cyanamide therapy.  Arch Pathol Lab Med. 1986;  110 (10) 906-910
• 13 Moreno A, Vazquez J J, Ruizdel Arbol L, Guillen F J, Colina F. Structural hepatic changes associated with cyanamide treatment: cholangiolar proliferation, fibrosis and cirrhosis.  Liver. 1984;  4 (1) 15-21
• 14 De Bruyne R, Portmann B, Samyn M et al.. Chronic liver disease related to 6-thioguanine in children with acute lymphoblastic leukaemia.  J Hepatol. 2006;  44 (2) 407-410
• 15 O'Shea A-M, Wilson G J, Ling S C, Minassian B A, Turnbull J, Cutz E. Lafora-like ground-glass inclusions in hepatocytes of pediatric patients: a report of two cases.  Pediatr Dev Pathol. 2007;  10 (5) 351-357
• 16 Lefkowitch J H, Lobritto S J, Brown Jr R S et al.. Ground-glass, polyglucosan-like hepatocellular inclusions: A “new” diagnostic entity.  Gastroenterology. 2006;  131 (3) 713-718
• 17 Wisell J, Boitnott J, Haas M et al.. Glycogen pseudoground glass change in hepatocytes.  Am J Surg Pathol. 2006;  30 (9) 1085-1090
• 18 Robitaille Y, Carpenter S, Karpati G, DiMauro S D. A distinct form of adult polyglucosan body disease with massive involvement of central and peripheral neuronal processes and astrocytes: a report of four cases and a review of the occurrence of polyglucosan bodies in other conditions such as Lafora's disease and normal ageing.  Brain. 1980;  103 (2) 315-336
• 19 Li S-C, Chen C M, Goldstein J L et al.. Glycogen storage disease type IV: novel mutations and molecular characterization of a heterogeneous disorder.  J Inherit Metab Dis. 2010; January 8;  (Epub ahead of print)
• 20 Singh S, Ganesh S. Lafora progressive myoclonus epilepsy: a meta-analysis of reported mutations in the first decade following the discovery of the EPM2A and NHLRC1 genes.  Hum Mutat. 2009;  30 (5) 715-723
• 21 Striano P, Zara F, Turnbull J et al.. Typical progression of myoclonic epilepsy of the Lafora type: a case report.  Nat Clin Pract Neurol. 2008;  4 (2) 106-111
• 22 Yokota T, Ishihara T, Yoshida H, Takahashi M, Uchino F, Hamanaka S. Monoclonal antibody against polyglucosan isolated from the myocardium of a patient with Lafora disease.  J Neuropathol Exp Neurol. 1988;  47 (5) 572-577
• 23 Hashimoto K, Hoshii Y, Takahashi M et al.. Use of a monoclonal antibody against Lafora bodies for the immunocytochemical study of ground-glass inclusions in hepatocytes due to cyanamide.  Histopathology. 2001;  39 (1) 60-65